About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72722 record(s)
Req # A-2023-001361
With respect to drug submission for aripiprazole which appears in the list of “Generic Drug Submissions Under Review” dated 2024-01-19, the initial cover letter(s) indicating the brand name of the reference drug product and the dosage form of the…Organization: Health Canada
September 2024
Req # A-2023-001420
All documents relating to the following medical devices: Company Identification (ID): 122369, Device name: 68882, DAP DIPHOTERINE and 68883, DAP HEXAFLUORINE, Company name: Prevor, Date range: 01 January 2003 to 01 Jan 2022.Organization: Health Canada
September 2024
Req # A-2023-001442
A list of external individuals/groups who provided responses to BOTH these external stakeholder consultations (Advanced Therapeutic Products (ATP) and Point of Care Chimeric Antigen Receptor T-cell (CAR T)), a list of the external representatives…Organization: Health Canada
September 2024
Req # A-2023-001451
The Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate, which was accepted into review on or after March 1, 2022 but before December 1, 2022, received a notice/letter from…Organization: Health Canada
September 2024
Req # A-2023-001606
The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Semaglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
September 2024
Req # A-2024-000043
All Instructions for Use (IFUs) for devices licensed under Medical Device License (MDL)106132 (RST DRUG OF ABUSE MULTI-TEST PANEL (URINE) II) and MDL105588 (RST DRUG OF ABUSE MULTI-TEST CUP (URINE) II) under Rapid Self Test Inc.Organization: Health Canada
September 2024
Req # A-2024-000126
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), provide a copy of the ANDS cover letter of the company (sponsor) who submitted the Second Semaglutide ANDS.Organization: Health Canada
September 2024
Req # A-2024-000256
The labels for all package types for all strengths or combinations of strengths of the final dosage forms which were included in the initial filing of the Abbreviated New Drug Submission (ANDS) for Tolvaptan from which was accepted into review in…Organization: Health Canada
September 2024
Req # A-2024-000266
All correspondence and other records relating to any pre-submission meeting(s) requested by the sponsor of the Degarelix Abbreviated Drug Submission (ANDS), and any pre-submission inquir(y/ies) submitted by the sponsor of the Degarelix ANDS.Organization: Health Canada
September 2024
Req # A-2024-000307
Communications between Dr. Michael Couthart, head of the Creutzfeldt-Jakob Disease Surveillance System, and other senior provincial government officials about the mystery brain illness experienced in New Brunswick. Time-frame: Oct. 1, 2023, to Dec.…Organization: Health Canada
September 2024